MBC Advocate

@kick_bans How long is the ban for ?

❌ Kick Partner "waxiest" has been banned! ❌ embed.kickbans.app/waxiest?b #kick #ban #partner #kickpartner 😉

“Preclinical data for AVA6103 (FAP-EXd) were matched with equivalent public domain data for Enhertu. The published data set for T-Dxd was recreated using an AI-model, with the equivalent also recreated for FAP-EXd using similar antigen-high models.” #AVCT trinitydelta.org/research-notes…

“Avacta’s pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis | Avacta Therapeutics.” #AVCT avacta.com/avactas-precis…

Independent DSMB has identified no safety concerns, and recommends continuation of BriaCell’s pivotal Phase 3 study of metastatic breast cancer Bria-IMT plus immune check point inhibitor. $BCTX $BCTXW finance.yahoo.com/news/briacell-…

CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference. $CYDY globenewswire.com/news-release/2…

Atossa decided to pause investment in (Z)-endoxifen for Metastatic Breast Cancer to focus on other diseases w/higher financial return.MBC patients were deprioritized not because science failed,but because our lives were not seen as profitable enough. $ATOS biopharmawatch.com/news/ATOS/atos…

DiviTum TKa data from the Ciclib trial published in JCO Precision. Results show that thymidine kinase activity (TKa) measured in blood can predict & dynamically track which patients respond to CDK4/6 inhibitor therapy in HR+/HER2‑ metastatic breast cancer. accessnewswire.com/newsroom/en/bi…

New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Metastatic Breast Cancer. $ALXO ir.alxoncology.com/news-releases/…

Our results add to the existing evidence that thymidine kinase 1 activity (TKa), measured using the DiviTum assay, provides prognostic information on progression free and overall survival in HR+/HER2− metastatic breast cancer treated w/first line CDK4/6. biospace.com/press-releases…

ImmunityBio and the SFDA initiated discussions for the expansion of ANKTIVA plus CPI into multiple tumor types in patients who have relapsed following checkpoint inhibitor therapy. These discussions build on the accelerated approval granted by SFDA. $IBRX immunitybio.com/immunitybio-re…

Puma Biotechnology ALISCA Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer. $PBYI investor.pumabiotechnology.com/news-releases/…

Real-world use and survival outcomes of sacituzumab govitecan in metastatic triple-negative breast cancer and hormone receptor-positive/HER2-negative metastatic breast cancer. nature.com/articles/s4141…

Treatment advances in metastatic breast cancer have led to prolongation in overall survival, nevertheless MBC is considered an incurable disease. Real-world data provides an opportunity to assess outcomes in SOC therapy and assess for potential curability. academic.oup.com/oncolo/advance…

There is an urgent need to include ER+/HER2- metastatic breast cancer in Avacta’s clinical trials. MBC is one of the fastest-growing cancers, increasingly affecting women under 35 and it remains incurable. No patient should be left behind. MBC must be included now. #AVCT

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Development Program of Novel Selective Estrogen Receptor Modulator SERM Represent Treatment Option for Patients w/ESR1-Mutations. $ATHA $LGND investor.ligand.com/news-and-event…

In loving memory of Anne Wipf, a gifted artist who created enchanted worlds of dreams and wonder. Her fairytale art continues to sparkle with magic and play. Though metastatic breast cancer took Anne from us, her spirit lives on through her art forever enchanting, forever loved.

Unforgettable Patricia Janečková her beautiful Pie Jesu had angelic quality. At only 25, taken by metastatic breast cancer too soon, her voice was so unique, one of the best. Her music remains a celestial beauty, forever lifting our hearts toward heaven.

No one is too young for cancer. Metastatic breast cancer is rising in women under 35, aggressive, relentless, and still without a cure. Heartbreaking loss of Christina Zajicek, taken far too soon by MBC at just 32 years old, so young, beautiful, and gone, but never forgotten. 💔

“ErSO-TFPy belongs to a new class of compounds that specifically target ERα+ metastatic breast cancer cells. It works by disrupting ionic balance inside the tumor cells, triggering extreme stress and a rapid, necrotic death.”

In loving memory of Anne Wipf, a remarkable artist who created magical worlds of beauty and wonder. Her carousel with horses running wild continues to inspire imagination.We lost Anne to metastatic breast cancer,her spirit lives on through her art,which will forever enchant us.💔